Skip to main content
Erschienen in: Clinical Rheumatology 2/2014

01.02.2014 | Original Article

Association of biomarkers of inflammation, cartilage and bone turnover with gender, disease activity, radiological damage and sacroiliitis by magnetic resonance imaging in patients with early spondyloarthritis

verfasst von: Raquel Almodóvar, Valeria Ríos, Sara Ocaña, Milena Gobbo, María-Luisa Casas, Pedro Zarco-Montejo, Xavier Juanola

Erschienen in: Clinical Rheumatology | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

To assess the association between biomarkers of inflammation, cartilage and bone turnover with gender, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Spondylitis Disease Activity Score (ASDAS) and bone marrow oedema in resonance magnetic imaging (MRI) of sacroiliac joints (SIJs) and radiological damage in early spondyloarthritis (SpA). Cross-sectional study of 60 patients (56.7 % females; mean age, 32.4 years) with early SpA. Sociodemographic data, clinical features, serum matrix metalloproteinase 3 (MMP-3), high sensitivity C-reactive protein (hsCRP), C-terminal cross-linking telopeptides of type I collagen (CTX-I) and urinary deoxypyridinoline, ASDAS, BASDAI, BASFI, BASRI and MRI of the SIJs were collected. The mean (SD) disease duration was 12.4 (6.8 months). Twenty-two (68.7 %) of the 32 patients had active sacroiliitis by MRI. MMP-3 and CTX I correlated with swollen joint (r = 0.515, r = 0.386, p = 0.01). hsCRP correlated with ESR (r = 0.303, p = 0.05), with CRP (r = 0.455, p = 0.01) and with total BASRI (r = 0.95, p = 0.05). Biomarkers were unrelated with the rest of variables. Levels of MMP-3 (44.3 ± 52.4 vs 24.7 ± 33.4, p < 0.05) and CTX-I (0.53 ± 0.45 vs 0.24 ± 0.38; p < 0.05) were higher in men. Our study shows that CTX-I and MMP-3 are a marker of peripheral disease activity in early SpA. Male gender had higher levels of CTX-I and MMP-3, which may indicate higher disease activity. Higher hsCRP levels trended towards correlation with more baseline radiographic damage. Therefore, these biomarkers may help identify a subgroup of patients who will need closer monitoring and more intensive treatment.
Literatur
1.
2.
Zurück zum Zitat De Vlam K (2010) Soluble and tissue biomarkers in ankylosing spondylitis. Best Pract Res Clin Rheumatol 24:671–682PubMedCrossRef De Vlam K (2010) Soluble and tissue biomarkers in ankylosing spondylitis. Best Pract Res Clin Rheumatol 24:671–682PubMedCrossRef
3.
Zurück zum Zitat Poddubnyy DA, Rudwaleit M, Listing J, Braun J, Sieper J (2010) Comparison of a high sensitivity and standard C-reactive protein measurement in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis. Ann Rheum Dis 69:1338–1341PubMedCrossRef Poddubnyy DA, Rudwaleit M, Listing J, Braun J, Sieper J (2010) Comparison of a high sensitivity and standard C-reactive protein measurement in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis. Ann Rheum Dis 69:1338–1341PubMedCrossRef
5.
Zurück zum Zitat Chen CH, Lin KC, Yu DT et al (2006) Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity. Rheumatology (Oxford) 45:414–420CrossRef Chen CH, Lin KC, Yu DT et al (2006) Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity. Rheumatology (Oxford) 45:414–420CrossRef
6.
Zurück zum Zitat Maksymowych WP, Landewé R, Conner-Spady B et al (2007) Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. Arthritis Rheum 56:1846–1853PubMedCrossRef Maksymowych WP, Landewé R, Conner-Spady B et al (2007) Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. Arthritis Rheum 56:1846–1853PubMedCrossRef
7.
Zurück zum Zitat Toussirot E, Ricard-Blum S, Dumoulin G, Cedoz JP, Wendling D (1999) Relationship between urinary pyridinium cross-links, disease activity and disease subsets of ankylosing spondylitis. Rheumatology (Oxford) 38:21–27CrossRef Toussirot E, Ricard-Blum S, Dumoulin G, Cedoz JP, Wendling D (1999) Relationship between urinary pyridinium cross-links, disease activity and disease subsets of ankylosing spondylitis. Rheumatology (Oxford) 38:21–27CrossRef
8.
Zurück zum Zitat Park MC, Chung SJ, Park YB, Lee SK (2008) Bone and cartilage turnover markers, bone mineral density, and radiographic damage in men with ankylosing spondylitis. Yonsei Med J 30:288–294CrossRef Park MC, Chung SJ, Park YB, Lee SK (2008) Bone and cartilage turnover markers, bone mineral density, and radiographic damage in men with ankylosing spondylitis. Yonsei Med J 30:288–294CrossRef
9.
Zurück zum Zitat Pedersen SJ, Sørensen IJ, Garnero P et al (2011) ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNFα inhibitors. Ann Rheum Dis 70:1375–1381PubMedCrossRef Pedersen SJ, Sørensen IJ, Garnero P et al (2011) ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNFα inhibitors. Ann Rheum Dis 70:1375–1381PubMedCrossRef
10.
Zurück zum Zitat Pedersen SJ, Sørensen IJ, Lambert RG et al (2011) Radiographic progression is associated with resolution of systemic inflammation in patients with axial spondyloarthritis treated with tumor necrosis factor α inhibitors: a study of radiographic progression, inflammation on magnetic resonance imaging, and circulating biomarkers of inflammation, angiogenesis, and cartilage and bone turnover. Arthritis Rheum 63:3789–3800PubMedCrossRef Pedersen SJ, Sørensen IJ, Lambert RG et al (2011) Radiographic progression is associated with resolution of systemic inflammation in patients with axial spondyloarthritis treated with tumor necrosis factor α inhibitors: a study of radiographic progression, inflammation on magnetic resonance imaging, and circulating biomarkers of inflammation, angiogenesis, and cartilage and bone turnover. Arthritis Rheum 63:3789–3800PubMedCrossRef
11.
Zurück zum Zitat Fernández Carballido C (2010) Diagnosing early spondyloarthritis in Spain: the ESPERANZA program. [Article in Spanish]. Reumatol Clin 6:6–10PubMedCrossRef Fernández Carballido C (2010) Diagnosing early spondyloarthritis in Spain: the ESPERANZA program. [Article in Spanish]. Reumatol Clin 6:6–10PubMedCrossRef
12.
Zurück zum Zitat Muñoz-Fernández S, Carmona L, Collantes E et al (2011) A model for the development and implementation of a national plan for the optimal management of early spondyloarthritis: the Esperanza Program. Ann Rheum Dis 70:827–830PubMedCrossRef Muñoz-Fernández S, Carmona L, Collantes E et al (2011) A model for the development and implementation of a national plan for the optimal management of early spondyloarthritis: the Esperanza Program. Ann Rheum Dis 70:827–830PubMedCrossRef
13.
Zurück zum Zitat Rudwaleit M, Van Der Heijde D, Landewé R et al (2009) The development of Assessment of Spondyloarthritis International Society Classification Criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 68:777–783PubMedCrossRef Rudwaleit M, Van Der Heijde D, Landewé R et al (2009) The development of Assessment of Spondyloarthritis International Society Classification Criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 68:777–783PubMedCrossRef
14.
Zurück zum Zitat Rudwaleit M, Van Der Heijde D, Landewé R et al (2011) The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 70:25–31PubMedCrossRef Rudwaleit M, Van Der Heijde D, Landewé R et al (2011) The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 70:25–31PubMedCrossRef
15.
Zurück zum Zitat Dougados M, Van Der Linden S, Juhlin R et al (1991) The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 34:1218–1227PubMedCrossRef Dougados M, Van Der Linden S, Juhlin R et al (1991) The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 34:1218–1227PubMedCrossRef
16.
Zurück zum Zitat Calin A, Nakache JP, Gueguen A, Zeidler H, Mielants H, Dougados M (1999) Defining disease activity in ankylosing spondylitis: is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument? Rheumatology (Oxford) 39:878–882CrossRef Calin A, Nakache JP, Gueguen A, Zeidler H, Mielants H, Dougados M (1999) Defining disease activity in ankylosing spondylitis: is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument? Rheumatology (Oxford) 39:878–882CrossRef
17.
Zurück zum Zitat Lukas C, Landewé R, Sieper J et al (2009) Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 68:18–24PubMedCrossRef Lukas C, Landewé R, Sieper J et al (2009) Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 68:18–24PubMedCrossRef
18.
Zurück zum Zitat Van Der Heijde D, Lie E, Kvien TK et al (2009) ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 68:1811–1818PubMedCrossRef Van Der Heijde D, Lie E, Kvien TK et al (2009) ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 68:1811–1818PubMedCrossRef
19.
Zurück zum Zitat Calin A, Garrett S, Whitelock H et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21:2281–2285PubMed Calin A, Garrett S, Whitelock H et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21:2281–2285PubMed
20.
Zurück zum Zitat Mackay K, Mack C, Brophy S, Calin A (1998) The Bath Ankylosing Spondylitis Radiology Index (BASRI). A new validated approach to diseases assessment. Arthritis Rheum 41:2263–2270PubMedCrossRef Mackay K, Mack C, Brophy S, Calin A (1998) The Bath Ankylosing Spondylitis Radiology Index (BASRI). A new validated approach to diseases assessment. Arthritis Rheum 41:2263–2270PubMedCrossRef
21.
Zurück zum Zitat Rudwaleit M, Jurik AG, Hermann KG et al (2009) Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group. Ann Rheum Dis 68:1520–1527PubMedCrossRef Rudwaleit M, Jurik AG, Hermann KG et al (2009) Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group. Ann Rheum Dis 68:1520–1527PubMedCrossRef
22.
Zurück zum Zitat Vandooren B, Kruithof E, Yu DT et al (2004) Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and downregulation by tumor necrosis factor alpha blockade in spondylarthropathy. Arthritis Rheum 50:2942–2953PubMedCrossRef Vandooren B, Kruithof E, Yu DT et al (2004) Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and downregulation by tumor necrosis factor alpha blockade in spondylarthropathy. Arthritis Rheum 50:2942–2953PubMedCrossRef
23.
Zurück zum Zitat Arends S, Van Der Veer E, Groen H et al (2011) Serum MMP-3 level as a biomarker for monitoring and predicting response to etanercept treatment in ankylosing spondylitis. J Rheumatol 38:1644–1650PubMedCrossRef Arends S, Van Der Veer E, Groen H et al (2011) Serum MMP-3 level as a biomarker for monitoring and predicting response to etanercept treatment in ankylosing spondylitis. J Rheumatol 38:1644–1650PubMedCrossRef
24.
Zurück zum Zitat Yang C, Gu J, Rihl M et al (2004) Serum levels of matrix metalloproteinase 3 and macrophage colony-stimulating factor 1 correlate with disease activity in ankylosing spondylitis. Arthritis Rheum 51:691–699PubMedCrossRef Yang C, Gu J, Rihl M et al (2004) Serum levels of matrix metalloproteinase 3 and macrophage colony-stimulating factor 1 correlate with disease activity in ankylosing spondylitis. Arthritis Rheum 51:691–699PubMedCrossRef
25.
Zurück zum Zitat Arends S, Spoorenberg A, Houtman PM et al (2012) The effect of 3 years of TNF alpha blocking therapy on markers of bone turnover and their predictive value for treatment discontinuation in patients with ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res Ther 14:R98. doi:10.1186/ar3823 PubMedCentralPubMedCrossRef Arends S, Spoorenberg A, Houtman PM et al (2012) The effect of 3 years of TNF alpha blocking therapy on markers of bone turnover and their predictive value for treatment discontinuation in patients with ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res Ther 14:R98. doi:10.​1186/​ar3823 PubMedCentralPubMedCrossRef
26.
Zurück zum Zitat Lange U, Teichmann J, Stracke H (2000) Correlation between plasma TNF-alpha, IGF-1, biochemical markers of bone metabolism, markers of inflammation/disease activity, and clinical manifestations in ankylosing spondylitis. Eur J Med Res 5:507–511PubMed Lange U, Teichmann J, Stracke H (2000) Correlation between plasma TNF-alpha, IGF-1, biochemical markers of bone metabolism, markers of inflammation/disease activity, and clinical manifestations in ankylosing spondylitis. Eur J Med Res 5:507–511PubMed
27.
Zurück zum Zitat Macdonald AG, Birkinshaw G, Durham B, Bucknall RC, Fraser WD (1997) Biochemical markers of bone turnover in seronegative spondylarthropathy: relationship to disease activity. Br J Rheumatol 36:50–53PubMedCrossRef Macdonald AG, Birkinshaw G, Durham B, Bucknall RC, Fraser WD (1997) Biochemical markers of bone turnover in seronegative spondylarthropathy: relationship to disease activity. Br J Rheumatol 36:50–53PubMedCrossRef
28.
Zurück zum Zitat Ribbens C, Porras M, Franchimont N et al (2002) Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis 61:161–166PubMedCrossRef Ribbens C, Porras M, Franchimont N et al (2002) Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis 61:161–166PubMedCrossRef
29.
Zurück zum Zitat Yamanaka H, Matsuda Y, Tanaka M et al (2000) Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the 6 months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum 43:852–858PubMedCrossRef Yamanaka H, Matsuda Y, Tanaka M et al (2000) Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the 6 months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum 43:852–858PubMedCrossRef
30.
Zurück zum Zitat Visvanathan S, Wagner C, Marini JC et al (2008) Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. Ann Rheum Dis 67:511–517PubMedCentralPubMedCrossRef Visvanathan S, Wagner C, Marini JC et al (2008) Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. Ann Rheum Dis 67:511–517PubMedCentralPubMedCrossRef
31.
Zurück zum Zitat Maksymowych WP, Rahman P, Shojania K et al (2008) Beneficial effects of adalimumab on biomarkers reflecting structural damage in patients with ankylosing spondylitis. J Rheumatol 35:2030–2037PubMed Maksymowych WP, Rahman P, Shojania K et al (2008) Beneficial effects of adalimumab on biomarkers reflecting structural damage in patients with ankylosing spondylitis. J Rheumatol 35:2030–2037PubMed
Metadaten
Titel
Association of biomarkers of inflammation, cartilage and bone turnover with gender, disease activity, radiological damage and sacroiliitis by magnetic resonance imaging in patients with early spondyloarthritis
verfasst von
Raquel Almodóvar
Valeria Ríos
Sara Ocaña
Milena Gobbo
María-Luisa Casas
Pedro Zarco-Montejo
Xavier Juanola
Publikationsdatum
01.02.2014
Verlag
Springer London
Erschienen in
Clinical Rheumatology / Ausgabe 2/2014
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-013-2349-5

Weitere Artikel der Ausgabe 2/2014

Clinical Rheumatology 2/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.